UNIGE document Scientific Article
previous document  unige:19880  next document
add to browser collection

Myeloperoxidase and paraoxonase-1 in type 2 diabetic patients

Jornayvaz, F. R.
Published in Nutrition, Metabolism & Cardiovascular Diseases. 2009, vol. 19, no. 9, p. 613-619
Abstract BACKGROUND AND AIMS: Reduced high density lipoproteins (HDL) and increased oxidative stress are features of type 2 diabetes. Myeloperoxidase is an oxidative enzyme partly associated with HDL and causing HDL dysfunction. It is an independent risk factor for cardiovascular disease. Paraoxonase-1 is an HDL-associated enzyme that protects against cardiovascular disease and is reduced in diabetes. The present study examined if serum myeloperoxidase was (i) increased in type 2 diabetes, (ii) correlated with paraoxonase-1 activity. METHODS AND RESULTS: The study was based on cross-sectional analyses of serum myeloperoxidase and paraoxonase-1 in type 2 diabetic patients and non-diabetic participants, with and without cardiovascular disease. Serum myeloperoxidase concentrations were not increased in type 2 diabetic patients without cardiovascular disease compared to non-diabetic controls. They were significantly higher in type 2 patients and non-diabetic patients with angiographically confirmed coronary disease. HDL-associated myeloperoxidase was correlated with serum myeloperoxidase (r=0.80, p<0.001) but not HDL-cholesterol (r=0.08) or apolipoprotein AI (r=0.08). Multivariate analyses showed serum myeloperoxidase to be an independent determinant of paraoxonase activities (arylesterase, p=0.024; paraoxonase, p=0.026). CONCLUSIONS: Myeloperoxidase is an independent, negative determinant of paraoxonase-1 activity, which may be one mechanism by which it promotes HDL dysfunction and increases cardiovascular risk. Increased serum myeloperoxidase is not a feature of type 2 diabetes in the absence of overt cardiovascular disease. The level of HDL-associated myeloperoxidase is determined by the serum concentration of the enzyme suggesting that, in the context of reduced HDL concentrations in diabetic patients, myeloperoxidase may have a greater impact on HDL function.
Keywords AdultAgedApolipoprotein A-I/bloodAryldialkylphosphatase/*bloodCoronary Artery Disease/blood/epidemiologyCross-Sectional StudiesDiabetes Mellitus, Type 2/*blood/*epidemiologyEnzyme Activation/physiologyFemaleHumansLipoproteins, HDL/bloodMaleMiddle AgedMultivariate AnalysisOxidative Stress/*physiologyPeroxidase/*bloodPredictive Value of TestsRisk Factors
PMID: 19201174
Full text
Research group Lipoprotéines sériques (598)
(ISO format)
JORNAYVAZ, F. R., BRULHART-MEYNET, Marie-Claude, JAMES, Richard William. Myeloperoxidase and paraoxonase-1 in type 2 diabetic patients. In: Nutrition Metabolism and Cardiovascular Diseases, 2009, vol. 19, n° 9, p. 613-619. https://archive-ouverte.unige.ch/unige:19880

251 hits

0 download


Deposited on : 2012-04-23

Export document
Format :
Citation style :